Cargando…
Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer
BACKGROUND: Breast cancer is the second most common cancer worldwide, the most common among women, and the most frequent cause of death among women in less developed regions. Trastuzumab is a humanized monoclonal antibody that downregulates the extracellular domain of the HER2 protein. Using trastuz...
Autores principales: | Gershon, Noga, Berchenko, Yakir, Hall, Peter S., Goldstein, Daniel A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396469/ https://www.ncbi.nlm.nih.gov/pubmed/30867655 http://dx.doi.org/10.1186/s12962-019-0174-7 |
Ejemplares similares
-
Affordability of comprehensive community health worker programmes in rural sub-Saharan Africa
por: Taylor, Celia, et al.
Publicado: (2017) -
Disentangling regional trade agreements, trade flows and tobacco affordability in sub-Saharan Africa
por: Appau, Adriana, et al.
Publicado: (2017) -
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
por: Hajjar, Ali, et al.
Publicado: (2019) -
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
por: Genuino, Anne Julienne, et al.
Publicado: (2019) -
Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)